KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBIT: 2017-2024

Historic EBIT for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to -$162.5 million.

  • Adaptive Biotechnologies' EBIT rose 131.53% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.2 million, marking a year-over-year increase of 60.86%. This contributed to the annual value of -$162.5 million for FY2024, which is 28.40% up from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' EBIT is -$162.5 million, which was up 28.40% from -$227.0 million recorded in FY2023.
  • In the past 5 years, Adaptive Biotechnologies' EBIT ranged from a high of -$152.8 million in FY2020 and a low of -$227.0 million during FY2023.
  • In the last 3 years, Adaptive Biotechnologies' EBIT had a median value of -$200.2 million in 2022 and averaged -$196.6 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' EBIT crashed by 94.94% in 2020 and then rose by 28.40% in 2024.
  • Adaptive Biotechnologies' EBIT (Yearly) stood at -$152.8 million in 2020, then plummeted by 36.74% to -$209.0 million in 2021, then climbed by 4.20% to -$200.2 million in 2022, then decreased by 13.41% to -$227.0 million in 2023, then climbed by 28.40% to -$162.5 million in 2024.